LONDON and NEW YORK, November 6 /PRNewswire/ --

Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on novel, anti-inflammatory drugs, today announced positive data from its ICH compliant Phase II equivalent multi-center study of MRX-4 (n=105) in patients suffering from allergic rhinitis. MRX-4 was given as an intranasal spray formulation.

WALTHAM, Massachusetts, November 6 /PRNewswire/ --

What: Yiannis Pavlosoglou, senior director in EMEA for Ounce Labs, industry leader in static application security ( http://www.ouncelabs.com/resources/application-vulnerabilities-faq.asp ) testing (SAST), will present a session titled 'Hybrid Code Auditing: A Dataflow Source Code Review Methodology' at DeepSec 2008 this week in Vienna, Austria.

Session Overview:

CHICAGO, November 6 /PRNewswire/ --

- Handset Pairs with Mobile Phone for Loud and Clear Communication on the Water

Cobra Electronics (Nasdaq: COBR) today announced the launch of a new marine product that will revolutionize the way boaters communicate. The patent-pending MR F300 BT EU handset uses Cobra's exclusive MicroBlue(TM) technology that enables boaters to have loud and clear non-emergency mobile phone conversations while underway.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081106/AQTH502LOGO)

TORONTO, November 6 /PRNewswire/ -- Patheon (TSX:PTI), a global provider of drug development and manufacturing services to the international pharmaceutical industry, today announced the opening of its new headquarters for its European operations in Zug, Switzerland, near Zurich. The new headquarters will manage the Company's commercial and pharmaceutical development services sales, marketing and customer support activities in Europe. Certain support functions will be managed in Zug as well, such as procurement and supply chain.

CALGARY, Canada, November 6 /PRNewswire/ --

- Successful Tertiary Aged Pila Spi Formation Appraisal Well

Addax Petroleum Corporation (Addax Petroleum or the Corporation) (TSX:AXC and LSE:AXC) today announces the successful appraisal of the Eocene Pila Spi formation in the Taq Taq field with the TT-11 appraisal and development well. The TT-11 well was recently drilled by Taq Taq Operating Company, the joint venture company formed by Genel Enerji A.S. and Addax Petroleum to carry out petroleum operations in the Taq Taq license area.

HONG KONG, November 6 /PRNewswire/ --

- From 64 countries around the world, 250 teachers, school administrators and education policymakers meet to reward educator excellence.

Today in Hong Kong, teachers were recognized for their creativity and innovation in the classroom as part of Microsoft Corp.'s 2008 Worldwide Innovative Teachers Forum (ITF). Now in its fourth year, the Worldwide ITF rewards outstanding teachers who practice exceptional 21st century learning and incorporate the creative use of technology in their classrooms.

(Logo: http://www.newscom.com/cgi-bin/prnh/20000822/MSFTLOGO )

LONDON, November 6 /PRNewswire/ -- Danfoss Drives and its partners now offer online ordering of the VLT(R) Micro Drive. Customers can order customised drives through a special web site and take delivery from their local distributor. The benefits include minimum processing time for orders, direct follow-up and the shortest possible delivery time.

The new web site, at http://www.vltmicro.co.uk, allows users to customise the drive, select their local distributor and pay for the order using PayPal or major credit cards.

TURKU, Finland, November 6 /PRNewswire/ -- BioCis Pharma Ltd a privately-held drug development company with its headquarters in Turku, Finland, announced that it has begun Phase IIa clinical testing of ProtoCure(TM) emulsion cream, the company's novel topical drug for dermatology. The double-blind, vehicle-controlled study is designed to evaluate the tolerability and efficacy of the topical product in a total of 18 subjects with mild to moderate forms of atopic dermatitis. The subjects will apply ProtoCure(TM) emulsion cream up to four weeks to the skin areas affected by the disease.

VANCOUVER, Canada, November 6 /PRNewswire/ -- Burcon NutraScience Corporation (TSX-V: BU) announces today the appointment of BMO Capital Markets to act as exclusive financial advisor to Burcon in connection with a process to identify and pursue strategic alternatives for the commercialization of its innovative food technology.

In engaging BMO Capital Markets, Burcon is initiating an extensive review of alternative strategies for maximizing shareholder value arising from Burcon's intellectual property portfolio including the recently announced soy protein isolate technology and CLARISOY(TM).

NOVATO, California, November 6 /PRNewswire/ --

- Enters Collaboration on Receptor Associated Protein (RAP)

- Supports NeuroTrans(TM) Platform with Japanese Patent

Raptor Pharmaceuticals Corp. (Raptor or the Company) (OTC Bulletin Board: RPTP), today announced updates on its preclinical program which utilizes drug-targeting platforms derived from the human receptor-associated protein (RAP) and related proteins. The Company signed a collaborative research agreement with the Brigham and Women's Hospital involving the characterization of certain modified RAP proteins. At the Hospital, this research will be conducted in the laboratory of Dr. Stephen Blacklow. The Company has also announced today a patent issuance in Japan relating to the NeuroTrans(TM) program.